Immunosenescence

Celularity CEO to Present on Cell Therapy’s Potential to Improve Longevity at 2024 ABUNDANCE Summit

Retrieved on: 
Thursday, March 14, 2024
CELU, Cell, Tissue, Research, Sarcopenia, Cornell University, Cancer, Biology, Pulse, Regenerative medicine, Immunity, Placenta, Singularity Group, Immunosenescence, Movement, Autoimmunity, Ageing, Medicine

Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.

Key Points: 
  • Dr. Hariri’s presentation, titled “The Cell Therapy Basis for Longevity,” will discuss the potential for using cellular therapeutics to address the biological ravages of aging by combating immunosenescence, sarcopenia and degenerative diseases.
  • Dr. Hariri has led the effort to harness the unique biology of placental-derived cells in a range of clinical indications, including cancer, autoimmune and degenerative diseases.
  • “Dr.
  • This work puts Dr. Hariri at the forefront of the longevity movement, with his finger on the pulse of the ever-changing landscape.”
    The ABUNDANCE Summit will occur in Los Angeles, Calif., from March 17 through 21, 2024.

TA-65: A Revolutionary Health Supplement Enhancing Immunity and Mitigating Inflammation in Heart Attack Patients

Retrieved on: 
Wednesday, June 21, 2023
Myocardial infarction, Infection, Ageing, Immunity, James Cook University Hospital, TA-65, Research, Inflammation, Cell, Immunosenescence, Patient, Risk, Immune system, Newcastle University, Health, Pharmaceutical industry, Medical device, Dentistry

NEWCASTLE, England, June 21, 2023 /PRNewswire-PRWeb/ -- A groundbreaking study led by Professor Ioakim Spyridopoulos of Newcastle University showcases the promising potential of TA-65®, a dietary supplement, in improving patient outcomes after a heart attack.

Key Points: 
  • The research, published in GeroScience, indicated that TA-65® reduced inflammation by up to 62% and increased immune cell count, thus strengthening patient immunity.
  • The supplement also supports mitochondrial health, contributing to patient vitality.
  • TA-65® is now seen as a valuable tool for addressing immunosenescence, the aging of the immune system, after a heart attack.
  • Remarkably, the study, published in GeroScience, revealed that TA-65® not only significantly reduced inflammation by up to 62%, but also increased the number of immune cells, enhancing the immunity of patients.

I'm over 65 and worried about the flu. Which vaccine should I have?

Retrieved on: 
Thursday, June 1, 2023
Vaccine, Infection, Heart, Immunology, Australian Technical Advisory Group on Immunisation, Vaccination, Immunization, National Immunisation Program Schedule, Fever, Cancer, Therapeutic Goods Administration, Working group, Immunity, MF59, COVID, Inflammation, Antibody, Cough, Adaptive immune system, Death, Mask, Immunosenescence, Risk, Immune system, Viral, N95, Sneeze, Ageing, TGA, Headache, Meat, Influenza vaccine, H1N1

It can cause the sudden onset of a fever, cough, runny nose, sore throat, headache, muscle and joint pain.

Key Points: 
  • It can cause the sudden onset of a fever, cough, runny nose, sore throat, headache, muscle and joint pain.
  • In Australia, the flu is responsible for more than 5,000 hospitalisation and 100 deaths a year.
  • To combat the decline in immunity as we age, specific vaccines are available for people aged 65 and over.

Remind me, how does the immune system work?

    • The immune system uses multiple mechanisms to fight viral infections, which can be divided into two major arms of the immune system, called innate and adaptive immunity.
    • Innate immunity involves multiple inflammatory cells and chemicals that are triggered immediately, or within hours of encountering an infection.

Why are older people more at risk from the flu?

    • This immune system decline is called immunosenescence, which leads to increased susceptibility, hospitalisation and death from influenza.
    • Certain medical conditions, such as cancer and heart and lung conditions, increase susceptibility to severe influenza, with older people being more likely to have additional medical conditions than younger people.

What flu vaccines are available?

    • Annual flu vaccines are recommended to protect against the common circulating strains of influenza, which can differ from year to year.
    • The standard flu vaccines offered to adults aged under 65 consist of surface proteins of the virus or inactivated (killed) virus from four influenza strains: two A strains (H1N1 and H3N2) and two B strains.
    • Read more:
      Why can you still get influenza if you've had a flu shot?

How do they compare?

    • In the few studies comparing Fluad and Fluzone directly, there is little evidence of a difference between them in reducing influenza and serious flu outcomes.
    • Fluzone is only available with a private prescription if you’re 60 years and over, at a cost of around A$65-70.
    • If neither augmented vaccine is available, a standard influenza vaccine is also acceptable for older people, since any influenza vaccine is preferable to receiving none.

How else can we protect against the flu?

    • Wearing a mask or N95 respirator significantly reduces the risk of infecting others when infected.
    • The evidence for protecting oneself against infection is less conclusive, mainly because it’s linked to early, consistent and, importantly, the correct use of masks.
    • Read more:
      Over half of eligible aged care residents are yet to receive their COVID booster.

Qu Biologics and Karolinska Institute Initiate Important New Collaboration to Validate Molecular Mechanisms of Qu Biologics’ First-in-Class Immunotherapy Platform

Retrieved on: 
Wednesday, December 14, 2022
Site, BC Cancer Agency, Ulcerative colitis, SSI, Associate, CD, Inflammation, Partnership, Lung cancer, Science, Epithelium, News, Cancer, Biotechnology, Inflammatory Bowel Diseases, KI, Infection, GI, Ethics, Crohn's disease, Conditional sentence, Fuxing (train), Pathology, Gene, HIV disease progression rates, Karolinska Institute, IBD, Disease, SSIS, Precision medicine, Immunosenescence, Medical laboratory, Division, Patient, Medical imaging, Vaccine, Pharmaceutical industry

Epithelial cells on mucosal surfaces are an important immune interface between microbial invaders and human tissue.

Key Points: 
  • Epithelial cells on mucosal surfaces are an important immune interface between microbial invaders and human tissue.
  • Loss of epithelial barrier function is commonly seen in diseases associated with chronic inflammation and can be exceedingly challenging to resolve.
  • Despite the arsenal of immune suppressive medication used to treat IBD, most patients experience disease progression.
  • Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Qu Biologics to Receive Additional Funding to Support Innovative New Treatment to Restore Innate Immune Function in the Elderly

Retrieved on: 
Monday, October 17, 2022
News, Risk, Urinary tract infection, COPD, Infection, Achievement, VP, NRC, SSIS, SSI, Immunity, Immunosenescence, Biotechnology, Asthma, Research, BC Cancer Agency, Mortality, Cancer, Lung cancer, National Research Council, Disease, CEO, Site, Innovation, GLOBE, Ulcerative colitis, Forward-looking statement, Ageing, COVID-19, Conditional sentence, Vaccine, Pharmaceutical industry

Innate immunity declines with age, leaving the elderly at significantly higher risk of developing severe respiratory infections (like COVID-19), cancer, and other diseases.

Key Points: 
  • Innate immunity declines with age, leaving the elderly at significantly higher risk of developing severe respiratory infections (like COVID-19), cancer, and other diseases.
  • This support from NRC IRAP for the clinical development of Qu Biologics unique made-in-Canada solution addresses the significant unmet need for immune protection in the elderly.
  • Dr. Ted Steiner, Qu Biologics Chief Medical Officer, Infectious Diseases, added, This trial, if successful, would be transformative.
  • Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

Qu Biologics to Launch Phase 2B Clinical Trial to Assess Reduction of Postoperative Immune Suppression and Disease Progression in Patients with Late-Stage Colorectal Cancer

Retrieved on: 
Monday, September 26, 2022
BC Cancer Agency, VP, Center, Ethics, Sunnybrook Health Sciences Centre, Conditional sentence, Site, Hope, Colorectal cancer, GI, Innovation, SSIS, SSI, Achievement, Biomolecular Object Network Databank, Immunotherapy, Survival, Ottawa Hospital Research Institute, Patient, Infection, Lung cancer, NK, Cancer, Forward-looking statement, Gastroenterology, Health Canada, Liver disease, Ulcerative colitis, Immunosenescence, CEO, Liver, Clinical trial, Sunnybrook Research Institute, Biotechnology, GLOBE, HIV disease progression rates, Immune system, Medical imaging, Vaccine, Pharmaceutical industry

Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.

Key Points: 
  • Major surgery results in immune paralysis in the days following surgery that can contribute to cancer growth and metastases, leading to poor outcomes for cancer patients undergoing surgical treatment.
  • Dr. Hal Gunn, CEO of Qu Biologics, stated, A majority of patients diagnosed with cancer undergo surgery in the hope of cure.
  • This exciting study is designed to test whether we can prevent that postoperative immune suppression resulting in improved outcomes and survival.
  • Qu Biologics has completed four Phase 2 studies in lung cancer, Crohns disease, and ulcerative colitis.

Imagine What It's Like to Talk to Astronauts While They Are Orbiting the Earth. Indianapolis Children Got To Do Just That

Retrieved on: 
Wednesday, August 31, 2022
Orbit, Mathematics, CEO, Lindgren, International Space Station programme, Work, Research, Emergency medicine, Science, technology, engineering, and mathematics, The Children's Museum of Indianapolis, NASA TV, SpaceX Crew-4, Radio, SpaceX Crew-1, Museum, International Space Station, Humanities, Television, NASA, Children, Astronaut, Learning, Heritage, Vegetable, Water, Student, Old National Bank, Altitude, Human, Crew Dragon Demo-2, Immune system, ISS, Mobile, Cherokee heritage groups, Dynamos, The Children's Museum, Lettuce, Ice, Family, Toy, Communications satellite, Tutoring, Immunosenescence, Engineering, Science, Technology, Facebook

Ky (Anderson) followed up with, "How does water behave in space?" Everyone giggled as Lindgren gave a demonstration and said, "Water is absolutely amazing. We take advantage of orbiting laboratory to examine how fluids move and work in space. So here's a little example -- This is how we drink juice or water depending on if it's a hot or cold drink. And you can see if I push a little bit of water out here… it assumes the shape of a sphere. It's shaking a little bit and I'll release it from the straw."

Key Points: 
  • INDIANAPOLIS, Aug. 31, 2022 /PRNewswire-PRWeb/ -- Indianapolis area students got to 'space-out' with an actual astronaut who was orbiting Earth on the International Space Station (ISS) today.
  • Lindgren answered, "Back 25 years ago the only way astronauts could talk with their families back on the ground was with amateur radio with a ham radio.
  • We take advantage of orbiting laboratory to examine how fluids move and work in space.
  • And you can see if I push a little bit of water out here it assumes the shape of a sphere.

Tranquis Therapeutics to Present Preclinical Data on TQS-168 at ARDD 2022

Retrieved on: 
Monday, August 29, 2022
Health, Neurology, Other Health, General Health, Clinical Trials, Pharmaceutical, Biotechnology, University, Metabolism, ECG, Research, Degenerative disease, Survival, Gene, Therapy, Wolfson Centre for Age-Related Diseases, Ageing, Longevity, Mouse, Vital signs, Male, Immunosenescence, Quality of life, Gene expression, Cytokine, Neurodegeneration, University of Copenhagen Faculty of Health and Medical Sciences, Adult, Frailty index, ALS, Pharmaceutical industry, Dietary supplement

Treatment with TQS-168 also resulted in improvements in grip strength and treadmill running endurance, and a reduction in fat mass with no change in lean mass.

Key Points: 
  • Treatment with TQS-168 also resulted in improvements in grip strength and treadmill running endurance, and a reduction in fat mass with no change in lean mass.
  • TQS-168 was found to be well tolerated in healthy adult male subjects in a Phase 1 clinical trial.
  • Adverse events were mild and transient, and no abnormalities were observed in laboratory parameters, ECG, or vital signs.
  • Tranquis is a clinical-stage biopharmaceutical company developing a portfolio of small molecule therapeutics based on its unique approach of modulating PGC-1a to restore normal cell homeostasis and function.

Qu Biologics to Receive Additional Funding to Launch Clinical Trial for the Restoration of Innate Immune Function in the Elderly Following Health Canada Go-Ahead

Retrieved on: 
Wednesday, July 20, 2022
BC Cancer Agency, Infection, Conditional sentence, Severe acute respiratory syndrome coronavirus 2, Immunosenescence, GLOBE, Mortality, NRC, National Research Council, Trial of the century, Ulcerative colitis, VP, CEO, Forward-looking statement, Inflammatory bowel disease, Risk, Health Canada, Disease, COVID-19, Site, Urinary tract infection, Cancer, Achievement, Clinical trial, Innovation, Ageing, Biotechnology, SSIS, Lung cancer, Intelligent Medical Objects, SSI, Degenerative disease, Population, Letter, Vaccine, Pharmaceutical industry

With the receipt of Health Canadas No Objection Letter, the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has committed additional advisory services and conditional funding to support this important clinical study.

Key Points: 
  • With the receipt of Health Canadas No Objection Letter, the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) has committed additional advisory services and conditional funding to support this important clinical study.
  • QBKPN SSI is designed to restore and enhance innate immune function, the bodys first line of defense against all infections and other diseases such as cancer.
  • By restoring innate immunity, QBKPN is positioned to contain and clear viral and bacterial infections before they have had an opportunity to spread.
  • Qu Biologics does not assume any obligation to update any forward-looking statements except as required by law.

NASA, SpaceX Launch Climate Science Research, More to Space Station

Retrieved on: 
Friday, July 15, 2022
Spacecraft, Artemis, Soil, Biology, EDT, Scientific research on the International Space Station, CubeSat, Television, Nutrient, Outline of physical science, International Space Station, Ageing, Travel, Micro-g environment, NASA, Science, Jet Propulsion Laboratory, Dust, Cell, Kennedy, Atmosphere, Gene, Vaccine, Multimedia, EMIT, Carbon, Medicine, Dragon, Snow, Falcon, Education, Galveston National Laboratory, SpaceX Dragon, Kennedy Space Center, Biotechnology, ISS National Lab, 3D, Research, Environmental monitoring, NASA TV, SpaceX, Weather, Technology, Communications satellite, Mars, Moon, Immunosenescence

The spacecraft launched on a Falcon 9 rocket from Launch Pad 39A at Kennedy for the company's 25th commercial resupply services mission for NASA.

Key Points: 
  • The spacecraft launched on a Falcon 9 rocket from Launch Pad 39A at Kennedy for the company's 25th commercial resupply services mission for NASA.
  • It is scheduled to autonomously dock at the space station about 11:20 a.m. Saturday, July 16, and remain there for about a month.
  • Mineral dust blown into the air can travel significant distances and affectEarth's climate, weather, vegetation, and more.
  • BeaverCube is an education mission that will teach high school students aerospace science by having them design a CubeSat.